Over 90% of the volume of biopharmaceutical shipments are done with packages made up of foam based material. They suffer from high failure rates arising from poor insulation performance. Annually, ineffective insulation material results in a $35B loss to the industry because of temperature breaches.
Aerogels are known as the world's best insulation material, but the best isn't always affordable nor scalable. Krosslinker's patented aerogel platform technology addresses the major limitations in traditional aerogel fabrication and formulation by bringing down the cost by a third with 3-10x faster turnaround time, 5x more energy efficiency and ⅕ the capital expenditure. The company advocates the “single platform, multiple products'' concept in the field of aerogel innovation.